IFRX
Price
$1.31
Change
+$0.02 (+1.54%)
Updated
Sep 24, 11:55 AM (EDT)
Capitalization
88.07M
36 days until earnings call
SVRA
Price
$3.52
Change
+$0.04 (+1.15%)
Updated
Sep 24, 12:30 PM (EDT)
Capitalization
601.47M
43 days until earnings call
Interact to see
Advertisement

IFRX vs SVRA

Header iconIFRX vs SVRA Comparison
Open Charts IFRX vs SVRABanner chart's image
InflaRx
Price$1.31
Change+$0.02 (+1.54%)
Volume$1.3K
Capitalization88.07M
Savara
Price$3.52
Change+$0.04 (+1.15%)
Volume$1K
Capitalization601.47M
IFRX vs SVRA Comparison Chart in %
Loading...
IFRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SVRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IFRX vs. SVRA commentary
Sep 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IFRX is a Hold and SVRA is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 24, 2025
Stock price -- (IFRX: $1.30 vs. SVRA: $3.48)
Brand notoriety: IFRX and SVRA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IFRX: 37% vs. SVRA: 54%
Market capitalization -- IFRX: $88.07M vs. SVRA: $601.47M
IFRX [@Biotechnology] is valued at $88.07M. SVRA’s [@Biotechnology] market capitalization is $601.47M. The market cap for tickers in the [@Biotechnology] industry ranges from $97.36B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IFRX’s FA Score shows that 0 FA rating(s) are green whileSVRA’s FA Score has 0 green FA rating(s).

  • IFRX’s FA Score: 0 green, 5 red.
  • SVRA’s FA Score: 0 green, 5 red.
According to our system of comparison, both IFRX and SVRA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IFRX’s TA Score shows that 4 TA indicator(s) are bullish while SVRA’s TA Score has 4 bullish TA indicator(s).

  • IFRX’s TA Score: 4 bullish, 5 bearish.
  • SVRA’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, both IFRX and SVRA are a bad buy in the short-term.

Price Growth

IFRX (@Biotechnology) experienced а +14.04% price change this week, while SVRA (@Biotechnology) price change was -4.13% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.31%. For the same industry, the average monthly price growth was +10.09%, and the average quarterly price growth was +53.86%.

Reported Earning Dates

IFRX is expected to report earnings on Oct 30, 2025.

SVRA is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+4.31% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SVRA($601M) has a higher market cap than IFRX($88.1M). SVRA YTD gains are higher at: 13.355 vs. IFRX (-47.368). IFRX has higher annual earnings (EBITDA): -44.6M vs. SVRA (-116.49M). SVRA has more cash in the bank: 146M vs. IFRX (48M). IFRX has less debt than SVRA: IFRX (599K) vs SVRA (29.7M). IFRX has higher revenues than SVRA: IFRX (163K) vs SVRA (0).
IFRXSVRAIFRX / SVRA
Capitalization88.1M601M15%
EBITDA-44.6M-116.49M38%
Gain YTD-47.36813.355-355%
P/E RatioN/AN/A-
Revenue163K0-
Total Cash48M146M33%
Total Debt599K29.7M2%
FUNDAMENTALS RATINGS
IFRX vs SVRA: Fundamental Ratings
IFRX
SVRA
OUTLOOK RATING
1..100
8380
VALUATION
overvalued / fair valued / undervalued
1..100
63
Fair valued
68
Overvalued
PROFIT vs RISK RATING
1..100
10063
SMR RATING
1..100
9899
PRICE GROWTH RATING
1..100
3842
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5090

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IFRX's Valuation (63) in the Biotechnology industry is in the same range as SVRA (68). This means that IFRX’s stock grew similarly to SVRA’s over the last 12 months.

SVRA's Profit vs Risk Rating (63) in the Biotechnology industry is somewhat better than the same rating for IFRX (100). This means that SVRA’s stock grew somewhat faster than IFRX’s over the last 12 months.

IFRX's SMR Rating (98) in the Biotechnology industry is in the same range as SVRA (99). This means that IFRX’s stock grew similarly to SVRA’s over the last 12 months.

IFRX's Price Growth Rating (38) in the Biotechnology industry is in the same range as SVRA (42). This means that IFRX’s stock grew similarly to SVRA’s over the last 12 months.

IFRX's P/E Growth Rating (100) in the Biotechnology industry is in the same range as SVRA (100). This means that IFRX’s stock grew similarly to SVRA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IFRXSVRA
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
72%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 1 day ago
77%
Momentum
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
78%
MACD
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
86%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
80%
Advances
ODDS (%)
Bullish Trend 7 days ago
78%
Bullish Trend 9 days ago
82%
Declines
ODDS (%)
Bearish Trend 9 days ago
86%
Bearish Trend 1 day ago
85%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
80%
Aroon
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
IFRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SVRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
WAMFX24.000.01
+0.04%
Boston Trust Walden Midcap
MCRTX66.23N/A
N/A
Morgan Stanley Insight R6
VGRTX83.99-0.04
-0.05%
JPMorgan US Value R2
SPMAX12.32-0.02
-0.16%
Saratoga Mid Capitalization A
FCUIX20.87-0.16
-0.76%
NYLI PineStone U.S. Equity Class I

IFRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, IFRX has been loosely correlated with PRTA. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if IFRX jumps, then PRTA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IFRX
1D Price
Change %
IFRX100%
-3.70%
PRTA - IFRX
34%
Loosely correlated
+0.24%
RCUS - IFRX
28%
Poorly correlated
-1.04%
VERA - IFRX
28%
Poorly correlated
-0.57%
NMRA - IFRX
26%
Poorly correlated
+10.40%
GPCR - IFRX
26%
Poorly correlated
-1.80%
More

SVRA and

Correlation & Price change

A.I.dvisor indicates that over the last year, SVRA has been loosely correlated with RCKT. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if SVRA jumps, then RCKT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SVRA
1D Price
Change %
SVRA100%
-0.29%
RCKT - SVRA
60%
Loosely correlated
-2.52%
PRTA - SVRA
45%
Loosely correlated
+0.24%
OCUL - SVRA
39%
Loosely correlated
+0.41%
IFRX - SVRA
39%
Loosely correlated
-3.70%
SRRK - SVRA
38%
Loosely correlated
+3.59%
More